检索结果 - Mark Heaney

Refine Results
  1. 1
    Refractory <i>Aspergillus</i> pneumonia in patients with acute leukemia

    Refractory <i>Aspergillus</i> pneumonia in patients with acute leukemia 由 Timothy Aliff, P. Maslak, Joseph G. Jurcic, Mark Heaney, Kathleen N. S. Cathcart, Kent A. Sepkowitz, Mark A. Weiss

    出版 2003
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Vitamin C Antagonizes the Cytotoxic Effects of Antineoplastic Drugs

    Vitamin C Antagonizes the Cytotoxic Effects of Antineoplastic Drugs 由 Mark Heaney, Jeffrey R. Gardner, Nicos Karasavvas, David W. Golde, David A. Scheinberg, Emily A. Smith, Owen A. O’Connor

    出版 2008
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    The Schedule-Dependent Effects of the Novel Antifolate Pralatrexate and Gemcitabine Are Superior to Methotrexate and Cytarabine in Models of Human Non-Hodgkin's Lymphoma

    The Schedule-Dependent Effects of the Novel Antifolate Pralatrexate and Gemcitabine Are Superior to Methotrexate and Cytarabine in Models of Human Non-Hodgkin's Lymphoma 由 Lorraine E. Toner, Radovan Vrḫovac, Emily A. Smith, Jeffrey R. Gardner, Mark Heaney, Mithat Gönen, Julie Teruya‐Feldstein, Frank Sirotnak, Owen A. O’Connor

    出版 2006
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia

    A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia 由 Prabodhika Mallikaratchy, Alessandro Ruggiero, Jeffrey R. Gardner, Vitaly Kuryavyi, William F. Maguire, Mark Heaney, Michael R. McDevitt, Dinshaw J. Patel, David A. Scheinberg

    出版 2010
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies

    The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies 由 Luca Paoluzzi, Mithat Gönen, Govind Bhagat, Richard R. Furman, Jeffrey R. Gardner, Luigi Scotto, Volodia D. Gueorguiev, Mark Heaney, Katia Manova, Owen A. O’Connor

    出版 2008
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma

    Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma 由 Luca Paoluzzi, Mithat Gönen, Jeffrey R. Gardner, Jill Mastrella, Dajun Yang, Jon Holmlund, Mel Sorensen, Lance Leopold, Katia Manova, Guido Marcucci, Mark Heaney, Owen A. O’Connor

    出版 2008
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    Pentostatin, Cyclophosphamide, and Rituximab Is an Active, Well-Tolerated Regimen for Patients With Previously Treated Chronic Lymphocytic Leukemia

    Pentostatin, Cyclophosphamide, and Rituximab Is an Active, Well-Tolerated Regimen for Patients With Previously Treated Chronic Lymphocytic Leukemia 由 Nicole Lamanna, Matt Kalaycio, P. Maslak, Joseph G. Jurcic, Mark Heaney, Renier J. Brentjens, Andrew D. Zelenetz, Denise Horgan, Alison N. Gencarelli, Katherine S. Panageas, David A. Scheinberg, Mark A. Weiss

    出版 2006
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Sequential Therapy With Fludarabine, High-Dose Cyclophosphamide, and Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia Produces High-Quality Responses: Molecular Remissions Predict for Durable Complete Responses

    Sequential Therapy With Fludarabine, High-Dose Cyclophosphamide, and Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia Produces High-Quality Responses: M... 由 Nicole Lamanna, Joseph G. Jurcic, Ariela Noy, P. Maslak, Alison N. Gencarelli, Katherine S. Panageas, Mark Heaney, Renier J. Brentjens, David W. Golde, David A. Scheinberg, Andrew D. Zelenetz, Mark A. Weiss

    出版 2008
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia

    Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia 由 Todd Rosenblat, Michael R. McDevitt, Deborah Mulford, Neeta Pandit‐Taskar, Chaitanya Divgi, Katherine S. Panageas, Mark Heaney, Suzanne Chanel, Alfred Morgenstern, George Sgouros, Steven M. Larson, David A. Scheinberg, Joseph G. Jurcic

    出版 2010
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics

    Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics 由 Mona D. Lee, Yuhong She, Michael J. Soskis, Christopher P. Borella, Jeffrey R. Gardner, Paula A. Hayes, Benzon M. Dy, Mark Heaney, Mark R. Philips, William G. Bornmann, Francis M. Sirotnak, David A. Scheinberg

    出版 2004
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  11. 11
    Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics

    Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics 由 Mona D. Lee, Yuhong She, Michael J. Soskis, Christopher P. Borella, Jeffrey R. Gardner, Paula A. Hayes, Benzon M. Dy, Mark Heaney, Mark R. Philips, William G. Bornmann, Francis M. Sirotnak, David A. Scheinberg

    出版 2004
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  12. 12
    Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium

    Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myel... 由 John Mascarenhas, Mark Heaney, Vesna Najfeld, Elizabeth O. Hexner, Omar Abdel‐Wahab, Raajit K. Rampal, Farhad Ravandi, Bruce Petersen, Gail J. Roboz, Eric J. Feldman, Nikolai A. Podoltsev, Dan Douer, Ross L. Levine, Martin S. Tallman, Ronald Hoffman

    出版 2012
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  13. 13
    Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of<i>JAK2 V617F</i>

    Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of<i>JAK2 V617F</i> 由 Brady L. Stein, Stephen T. Oh, Dmitriy Berenzon, Gabriela S. Hobbs, Marina Kremyanskaya, Raajit K. Rampal, Camille N. Abboud, Kenneth B. Adler, Mark Heaney, Elias Jabbour, Rami S. Komrokji, Alison R. Moliterno, Ellen K. Ritchie, Lawrence Rice, John Mascarenhas, Ronald Hoffman

    出版 2015
    获取全文
    Revisão
    加到收藏夹
    Saved in:
  14. 14
    Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics

    Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinet... 由 Daniel J. DeAngelo, Richard M. Stone, Mark Heaney, Stephen D. Nimer, Ronald Paquette, Rebecca B. Klisovic, Michael A. Caligiuri, Michael R. Cooper, Jean-Michel Lecerf, Michael D. Karol, Shihong Sheng, Nicholas H. G. Holford, Peter Curtin, Brian J. Druker, Michael C. Heinrich

    出版 2006
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  15. 15
    Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies

    Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignan... 由 Owen A. O’Connor, Mark Heaney, Lawrence B. Schwartz, Stacie Richardson, Robert D. Willim, Barbara MacGregor‐Cortelli, Tracey Curly, Craig H. Moskowitz, Carol S. Portlock, Steven M. Horwitz, Andrew D. Zelenetz, Stanley Frankel, Victoria M. Richon, Paul A. Marks, William Kevin Kelly

    出版 2005
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  16. 16
    Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease

    Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease 由 Eli L. Diamond, Lorenzo Dagna, David M. Hyman, Giulio Cavalli, Filip Janků, Juvianee Estrada‐Veras, Marina Ferrarini, Omar Abdel‐Wahab, Mark Heaney, Paul J. Scheel, Nancy Feeley, Elisabetta Ferrero, Kenneth L. McClain, Augusto Vaglio, Thomas V. Colby, Laurent Arnaud, Julien Haroche

    出版 2014
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  17. 17
    Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis

    Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis 由 Priya Koppikar, Omar Abdel‐Wahab, Cyrus V. Hedvat, Sachie Marubayashi, Jay Patel, Aviva Goel, Nicole Kucine, Jeffrey R. Gardner, Andrew P. Combs, Kris Vaddi, Patrick J. Haley, Timothy C. Burn, Mark Rupar, Jacqueline Bromberg, Mark Heaney, Elisa de Stanchina, Jordan S. Fridman, Ross L. Levine

    出版 2010
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  18. 18
    Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer

    Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer 由 William Kevin Kelly, Owen A. O’Connor, Lee M. Krug, Judy H. Chiao, Mark Heaney, Tracy Curley, Barbara MacGregore-Cortelli, William P. Tong, J. Paul Secrist, Lawrence B. Schwartz, Stacy Richardson, Elaina Chu, Semra Olgac, Paul A. Marks, Howard I. Scher, Victoria M. Richon

    出版 2005
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  19. 19
    ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial

    ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial 由 Stephen T. Oh, Moshe Talpaz, Aaron T. Gerds, Vikas Gupta, Srđan Verstovšek, Ruben A. Mesa, Carole B. Miller, Candido E. Rivera, Angela G. Fleischman, Swati Goel, Mark Heaney, Casey L. O’Connell, Murat O. Arcasoy, Yafeng Zhang, Jun Kawashima, Tomas Ganz, Mark Kowalski, Carrie Baker Brachmann

    出版 2020
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  20. 20
    Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms

    Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms 由 Raajit K. Rampal, John Mascarenhas, Heidi E. Kosiorek, Leah Price, Dmitriy Berenzon, Elizabeth O. Hexner, Camille N. Abboud, Marina Kremyanskaya, Rona Singer Weinberg, Mohamed E. Salama, Kamal Menghrajani, Vesna Najfeld, Lonette Sandy, Mark Heaney, Ross L. Levine, Ruben A. Mesa, Amylou C. Dueck, Judith D. Goldberg, Ronald Hoffman

    出版 2018
    获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: